Psoriasis and Beyond - Interim results

02 July 2021


Experts will gather virtually at the 6th World Psoriasis and Psoriatic Arthritis Conference to discuss the latest breakthroughs in psoriasis and psoriatic arthritis. While the greatest minds in rheumatology and dermatology join forces to boost understanding of all aspects of these serious chronic illnesses, the global community will also get a first glimpse of interim results from Psoriasis and Beyond: Global Psoriatic Disease Survey.

About Psoriasis and Beyond

Psoriasis and Beyond: Global Psoriatic Disease Survey - is a joint research initiative shared by IFPA and Novartis, in collaboration with psoriatic disease advocates and dermatology experts.

The Psoriasis and Beyond study explored the complexity of psoriatic disease and its associated comorbidities by collecting patient-reported perspectives from almost 5,000 participants in 20 countries. The presentation of the interim results marks the very first milestone in sharing this new evidence of the impact of illness on everyday experiences, including social and personal life, self-esteem and emotional consequences. The joint psoriatic disease aimed to capture the psoriatic disease spectrum, and focus on people living with moderate and severe plaque psoriasis and psoriatic arthritis. It is expected that final results will inform evidence-based messages to support policy and advocacy efforts, closing the gap between knowledge and action.

Professor April Armstrong presents interim results at the 6th World Psoriasis & Psoriatic Arthritis Conference highlighting psoriasis as more than skin deep.

IFPA thanks the psoriatic disease community for speaking up. Your motivation has made this large, international study possible. We look forward to sharing final findings before the end of 2021.

Image source: Psoriasis and Beyond. Assets belong to the Psoriasis and Beyond campaign